abstract |
A binding molecule capable of binding to L1, (a) being selected from the group consisting of single chain antibodies, scFv, scFv multimers such as diabodies, triabodies or tetrabodies, antibody fragments, Fab, Tandabs, Flexibodies, bispecific antibodies and chimeric antibodies , and / or (b) comprising at least one lg domain, and in which the binding molecule capable of binding to L1: (i) is characterized in that its complementarity determining regions (CDR) have the following sequences: LCDR1: RASQDISNYLN (SEQ ID No .: 24), LCDR2: YTSRLHS (SEQ ID No .: 25), LCDR3: QQGNTLPWT (SEQ ID No .: 26), HCDR1: RYWML (SEQ ID No .: 27), HCDR2: EINPRNDRTNYNEKFKT ( SEQ ID No .: 28) and HCDR3: GGGYAMDY (SEQ ID No .: 29), and whose binding molecule binds to L1 with an affinity (KD) of at least 10-10 M, or (ii) is characterized in that its complementarity determining regions (CDR) have the following sequences: LCDR1: QDISNY (SEQ ID No .: 30), LCDR2: YTS, LCDR3: QQGNTLPWT (SEQ I D No .: 31), HCDR1: GYTFTRYW (SEQ ID No .: 32), HCDR2: INPRNDRT (SEQ ID No .: 33), and HCDR3: ALGGGYAMDY (SEQ ID No .: 34), and whose binding molecule is binds L1 with an affinity (KD) of at least 10-10 M. |